Monoox (Ofloxacin)

Ofloxacin inhibits bacterial DNA gyrase and topoisomerase IV, enzymes required for DNA replication and transcription. By blocking these enzymes, the drug prevents bacterial cell division, leading to bacterial death and clearance of the infection in the ocular tissues.

The dosing regimen for Monoox is determined by the prescribing ophthalmologist based on the severity of the infection, patient age and response to therapy. The prescriber will specify the number of drops, frequency and duration of treatment.

Safety data for Ofloxacin in pregnancy and lactation are limited, and the product is classified as having an unknown pregnancy category. Clinicians should weigh potential benefits against risks and consider alternative treatments when treating pregnant or nursing patients.

To request Monoox, submit an enquiry on the product page at gnhindia.com, indicating the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Monoox (Ofloxacin) is a fluoroquinolone, offering broad‑spectrum coverage against Gram‑negative and some Gram‑positive ocular pathogens. Compared with older agents such as chloramphenicol, Ofloxacin generally provides higher potency and a lower risk of resistance, though choice depends on local susceptibility patterns and patient factors.

Monoox should be stored at room temperature, below 25 °C, in its original container. Protect the product from direct sunlight, moisture and extreme temperatures to maintain stability and potency throughout its shelf life.

Monoox is applied as an eye drop. The prescriber will instruct the patient on the number of drops per eye, the frequency (e.g., one drop every 2–4 hours), and the total duration of therapy, ensuring proper technique to avoid contamination.

Serious risks, though rare, include severe allergic reactions such as swelling, rash or anaphylaxis, Stevens‑Johnson syndrome, and significant ocular inflammation that can lead to vision loss. Patients should seek immediate medical attention if they experience these symptoms.

Monoox should not be used by individuals with a known hypersensitivity to Ofloxacin, other fluoroquinolones, or any component of the formulation. It is also contraindicated in patients with a history of tendon disorders related to fluoroquinolone use.